1 |
Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia[J]. Lancet, 2018, 391(10116): 155-167.
|
2 |
Oikonomopoulou C, Goussetis E. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe[J]. Bone Marrow Transplantat, 2021, 56(12): 2882-2888.
|
3 |
Swaminathan VV, Uppuluri R, Patel S, et al. Matched family versus alternative donor hematopoietic stem cell transplantation for patients with thalassemia major: experience from a tertiary referral center in South India[J]. Bio Blood Marrow Transplant, 2020, 26(7): 1326-1331.
|
4 |
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)——急性移植物抗宿主病(2020年版) [J]. 中华血液学杂志,2020, 41(7): 529-536.
|
5 |
徐昊立,王雄虎,陈婷婷,等. 2011—2021年广东省地中海贫血及胎儿水肿综合征监测分析[J]. 华南预防医学,2023, (9): 1093-1097.
|
6 |
Ahmed S, Soliman A, De Sanctis V, et al. A short review on growth and endocrine long-term complications in children and adolescents with β-thalassemia major: conventional treatment versus hematopoietic stem cell transplantation[J]. Acta Biomedica, 2022, 93(4): e2022290.
|
7 |
Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major[J]. Br J Haematol, 2010, 148(3): 466-475.
|
8 |
Chai ASC, Draman N, Yusoff SSM, et al. Non-compliance to iron chelation therapy in patients with transfusion-dependent thalassaemia[J]. Pediatr Hematol Oncol J, 2021, 6(4): 207-215.
|
9 |
Fortin PM, Fisher SA, Madgwick KV, et al. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia [J]. Cochrane Database Syst Rev, 2018, 5(5): CD012349.
|
10 |
Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010[J]. Bone Marrow Transplant, 2016, 51(4): 536-541.
|
11 |
陈诗杨,付笑迎,徐刚,等. 重型β-地中海贫血患儿异基因造血干细胞移植术后淋巴细胞亚群重建分析[J]. 检验医学,2019, 34(12): 1066-1071.
|
12 |
曹勋红,余星星,胡利娟,等. 异基因造血干细胞移植后NK细胞免疫重建的研究进展[J]. 现代免疫学,2019, 39(1): 64-67.
|
13 |
李欢,邓建川,娄世锋,等. 异基因造血干细胞移植后淋巴细胞亚群重建情况的相关因素分析研究[J]. 医学检验与临床,2021, 32(11): 31-38.
|
14 |
胡彬,黄斯勇,梁英民. microRNA与急性移植物抗宿主病研究进展[J]. 中华血液学杂志,2015,36(10):894-896.
|
15 |
Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moёlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study[J]. Blood, 2005, 106(4): 1495-1500.
|
16 |
Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism[J]. Blood, 2007, 110(7): 2235-2241.
|
17 |
Mytilineos D, Tsamadou C, Neuchel C, et al. The human leukocyte antigen-DPB1 degree of compatibility is determined by its expression level and mismatch permissiveness: a German multicenter analysis[J]. Front Immunol, 2020, 11: 614976.
|
18 |
Yan FH, Wang M, Yao JF, et al. Impact of human leukocyte antigen loci and haplotypes on intestinal acute graft-versus-host disease after human leukocyte antigen-matched sibling peripheral blood stem cell transplantation [J]. Chin Med J (Engl), 2017, 130(11): 1290-1295.
|
19 |
Yang F, Lu D, Hu Y, et al. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the China Marrow Donor Program[J]. Ann Transplant, 2017, 22: 384-401.
|
20 |
Li X, Lin X, Mei X, et al. HLA3D: an integrated structure-based computational toolkit for immunotherapy[J]. Brief Bioinform, 2022, 23(3):bbac076.
|
21 |
Suzuki S, Morishima S, Murata M, et al. Sequence variations within HLA-G and HLA-F genomic segments at the human leukocyte antigen telomeric end associated with acute graft-versus-host disease in unrelated bone marrow transplantation[J]. Front Immunol, 2022, 13: 938206.
|
22 |
Delaney M, Cutler CS, Haspel RL, et al. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults[J]. Transfusion, 2009, 49(5): 995-1002.
|
23 |
Ho JCY, Cheung SKF, Lui Z, et al. Revisit of optimal donor number estimation in the Hong Kong Bone Marrow Donor Registry[J]. Front Immunol, 2021, 12: 638253.
|
24 |
Mittal S, Sinha P, Sarin S, et al. Impact of human leukocyte antigen compatibility on outcomes of living donor liver transplantation: experience from a tertiary care center[J]. Transpl Infect Dis, 2021, 23(4): e13644.
|
25 |
Song X, Qi J, Li X, et al. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases[J]. Platelets, 2023, 34(1): 2229905.
|
26 |
Merino A, Maakaron J, Bachanova V. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting[J]. Blood Rev, 2023, 60: 101073.
|
27 |
Song Q, Nasri U, Nakamura R, et al. Retention of donor T cells in lymphohematopoietic tissue and augmentation of tissue PD-L1 protection for prevention of GVHD while preserving GVL activity[J]. Front Immunol, 2022, 13: 907673.
|
28 |
Dekker L, Sanders E, Lindemans CA, et al. Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty?[J]. Front Immunol, 2022, 13: 893545.
|
29 |
Patey-Mariaud de Serre N, Reijasse D, Verkarre V, et al. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children[J]. Bone Marrow Transplant, 2002, 29(3): 223-230.
|
30 |
Vollmer M, Smith P, Bucher C, et al. Sphingosine-1-phosphate receptor-1 agonist averts the de novo generation of autoreactive T-cells in murine acute graft-versus-host disease[J]. Hemasphere, 2021, 5(8): e613.
|
31 |
Oh SJ, Cho SB, Park SH, et al. Cell cycle and immune-related processes are significantly altered in chronic GVHD[J]. Bone Marrow Transplant, 2008, 41(12): 1047-1057.
|